Publications by authors named "Pedro J Gomez-Arias"
Article Synopsis
- - Alopecia areata (AA) is an autoimmune condition that leads to hair loss, influenced by genetic and environmental factors, with recent studies suggesting that scalp microbiota may affect its progression through inflammatory responses.
- - A study with 24 participants analyzed the scalp microbiomes of those with varying severities of AA and healthy individuals, finding significant differences in microbial communities and their correlation with inflammation and AA severity.
- - Results showed that patients with severe AA had more pro-inflammatory bacteria, while those with milder forms had beneficial bacteria, indicating that scalp microbiota might be linked to AA inflammation, though further research is needed to understand the exact relationship.
Introduction: Tape-strips, a minimally invasive method validated for the evaluation of several skin diseases, may help identify asthma-specific biomarkers in the skin of children with allergic asthma.
Methods: Skin tape-strips were obtained and analyzed with RNA-Seq from children with moderate allergic asthma (MAA) (n = 11, mean age 7.00; SD = 1.
Introduction: This scoping review explores the effectiveness of IL-1 pathway inhibitors in managing PSTPIP1-associated inflammatory diseases (PAID). These diseases are marked by abnormal IL-1 pathway activation due to genetic mutations.
Methods: Our methodology adhered to a pre-published protocol and involved a thorough search of MEDLINE and EMBASE databases up to February 2022, following the Joanna Briggs Institute Reviewer's Manual and the PRISMA Extension for Scoping Reviews.
Background: This is the first report on the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the expression of skin biomarkers in patients with moderate-to-severe atopic dermatitis (AD).
Methods: JADE MOA (NCT03915496) was a double-blind Phase 2a trial. Adults were randomly assigned 1:1:1 to receive monotherapy with once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 weeks.
Article Synopsis
- The study investigates the differences between adult-onset atopic dermatitis (AOAD) and pediatric-onset atopic dermatitis persisting into adulthood (POAD), focusing on their unique characteristics to aid in targeted therapy development.
- Skin biopsies and blood samples from adults with AOAD, POAD, and healthy controls were analyzed using various techniques, revealing distinct immune responses and dysregulations in both conditions.
- Results indicated that while POAD showed more severe inflammation and epidermal barrier issues, AOAD had different immune marker expressions and a greater number of dysregulated proteins in serum, suggesting the need for diverse therapeutic strategies that go beyond just targeting Th2 pathways.
Background: The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway.
Methods: We evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open-label dupilumab for 24 weeks.
Introduction: The Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway are known to be involved in inflammatory immune-mediated skin diseases, including psoriasis. The development of drugs targeting the JAK/STAT signaling pathway presents new treatment opportunities for psoriasis. However, the application of JAK inhibitors for the treatment of dermatological disorders is still in its early stages of development.
View Article and Find Full Text PDFImportance: Type I interferon (IFN)-mediated monogenic autoinflammatory disorders (interferonopathies) are childhood-onset rare multisystemic diseases with limited treatment options. The Janus kinase (JAK) inhibitors are promising potential therapeutic candidates for immune-mediated chronic inflammatory skin diseases.
Objective: To review the use of JAK inhibitors to improve decision-making when treating interferonopathies with cutaneous manifestations.
Condyloma acuminata mimicking cutaneous microcystic lymphatic malformation.
Indian J Dermatol Venereol Leprol
December 2022
Introduction: The JAK/STAT signaling pathway is involved in the immune-mediated inflammatory skin diseases atopic dermatitis (AD), vitiligo, and alopecia areata (AA), and represents a potential target when developing treatments. So far, no drugs targeting this pathway have been approved for the treatment of dermatological diseases. We reviewed the use of drugs blocking the JAK/STAT pathway in the aforementioned diseases.
View Article and Find Full Text PDFIntroduction: The Janus kinase and Signal Transducer and Activator of Transcription protein (JAK/STAT) pathway is known to be involved in inflammatory and neoplastic skin diseases, like psoriasis, atopic dermatitis, alopecia areata, vitiligo and melanoma. Improved knowledge of the components of this pathway has allowed the development of drugs, which act by inhibiting the pathway, blocking specific components. This offers new therapeutic opportunities.
View Article and Find Full Text PDFThis research-on-research study describes efforts to develop non-Cochrane systematic reviews (SRs) by analyzing demographical and time-course collaborations between international institutions using protocols registered in the International Prospective Register of Systematic Reviews (PROSPERO) or published in scientific journals. We have published an a priori protocol to develop this study. Protocols published in scientific journals were searched using the MEDLINE and Embase databases; the query terms "Systematic review" [Title] AND "protocol" [Title] were searched from February 2011 to December 2017.
View Article and Find Full Text PDF